These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Checkpoint inhibitors in breast cancer: hype or promise? McArthur HL Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806 [No Abstract] [Full Text] [Related]
5. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors. Andtbacka RH Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099 [No Abstract] [Full Text] [Related]
6. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Schoenhals JE; Seyedin SN; Tang C; Cortez MA; Niknam S; Tsouko E; Chang JY; Hahn SM; Welsh JW Cancer J; 2016; 22(2):130-7. PubMed ID: 27111909 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Therapy in Melanoma. Callahan MK Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901 [TBL] [Abstract][Full Text] [Related]
8. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Santana-Davila R; Chow LQ Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785 [No Abstract] [Full Text] [Related]
9. Immunotherapy and lung cancer: current developments and novel targeted therapies. Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336 [TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. Marrone KA; Brahmer JR Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902 [TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Anagnostou VK; Brahmer JR Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707 [TBL] [Abstract][Full Text] [Related]
12. Clinical use of checkpoint inhibition in kidney cancer. Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812 [No Abstract] [Full Text] [Related]
13. Immunotherapeutic Approaches to Biliary Cancer. Shah UA; Nandikolla AG; Rajdev L Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Mooradian MJ; Sullivan RJ Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289 [TBL] [Abstract][Full Text] [Related]
17. Advancing Immunotherapy in Metastatic Breast Cancer. Mansour M; Teo ZL; Luen SJ; Loi S Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
20. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]